



Presentation Half-yearly Financial Report

14 July 2010

This communication contains certain forward-looking statements, relating to the Company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "will", "should", "future", "potential" or similar expressions or by general discussion of strategy, plans or intentions of the Company. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

Such factors include, among others, the following: uncertainties related to results of our clinical trials, the uncertainty of regulatory approval and commercial uncertainty, reimbursement and drug price uncertainty, the absence of sales and marketing experience and limited manufacturing capabilities, attraction and retention of technologically skilled employees, dependence on licenses, patents and proprietary technology, dependence upon collaborators, future capital needs and the uncertainty of additional funding, risks of product liability and limitations of insurance, limitations of supplies, competition from other biopharmaceutical, chemical and pharmaceutical companies, environmental, health and safety matters, availability of licensing arrangements, currency fluctuations, adverse changes in governmental rules and fiscal policies, civil unrest, acts of God, acts of war, and other factors referenced in this communication.

Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.

This material is not intended as an offer or solicitation for the purchase or sale of shares of WILEX AG. This material may not be distributed within countries where it may violate applicable law.

R & D

- REDECTANE[®]: Phase III trial – final data
- RENCAREX[®]: Phase III trial - 324 events
- MESUPRON[®]: Phase II trial in pancreatic cancer – final data
- MESUPRON[®]: Phase II trial in breast cancer - 84 patients recruited
- WX-554: Phase I trial in healthy volunteers - final data

Corporate

- Standby equity distribution agreement for up to € 20.00 m signed
- AGM elected new Supervisory Board and adopted all resolutions



→ **All planned milestones reached**



Financials

Key figures H1 2010



*€ m; rounded



- Net loss for the period € 11.56 m, 10.7% below H1 2009
- Earnings per share: € -0.73 (H1 2009: € -0.81)
- Other income at € 0.91 m, 19.8% below H1 2009
- Number of employees: 72

Operating expenses H1 2010




*€ million; rounded



- Operating expenses up 6.6% from the previous year due to higher R&D costs
- R&D expenses are 81.7% of total costs
- Administrative costs higher due to increased expenses from the measurement of stock options

Balance sheet as at 31 May 2010

*€ m; rounded



→ Cash balance as at 31.05.10 € 3.31 m

→ Average cash usage per month € 2.23 m (H1 2009: € 1.93 m per month) without milestone payment and cash capital increase

Corporate

- ✓ SEDA signed; Equity line over 36 months possible
- Commercialisation / Financing

REDECTANE®

- ✓ Final Phase III data and report
- Application for approval in preparation

RENCAREX®


- Announcement of 343 relapses in ARISER trial followed by interim analysis for efficacy 6 months later

MESUPRON®

- ✓ Final Phase II data in pancreatic cancer
- Completion of patient recruitment in Phase II breast cancer trial

WX-554

- ✓ Complete Phase I healthy volunteer study



*direct holdings

- Oncology-focused company
- Transition from R&D to commercially driven business
- Product candidates close to market
 - First-in-Class
 - Strong competitive profile
- Commercial deal opportunities in attractive indications
- Multiple value short-term inflexion points ahead

WILEX AG

Grillparzerstr. 10
81675 Munich, Germany
Tel.: +49 (0)89-41 31 38-0
Fax: +49 (0)89-41 31 38-99
Website: www.wilex.com

Corporate Communications

Katja Arnold (CIRO)
Email: investors@wilex.com
Tel.: +49 (0)89-41 31 38-126

ISIN: DE0006614720
Symbol: WL6
Reuters: WL6G.DE
Bloomberg: WL6G.GR